Understanding Ingredient Choices in the Context of Novel Foods: Why You Need More Than a Salesman's Assurance

The gold rush problem: popularity without professionalism

Functional and novel ingredients — CBD, adaptogens, nootropics, postbiotics, plant-based proteins, bioactive mushroom extracts — have become one of the fastest-growing areas of the consumer food and supplement market. Consumer demand is real, the commercial opportunity is significant, and the barriers to launching a product feel deceptively low. A formulator's quote, a contract manufacturer, a packaging designer, and an e-commerce platform — and a brand exists.

The problem is that the regulatory and technical complexity of bringing these products to market has not reduced to match the apparent ease of entry. If anything, it has increased. The FSA's enforcement posture on novel foods has hardened. Retailer requirements around certification, traceability, and substantiation have tightened. And the consumer and media scrutiny applied to brands making health-adjacent claims — or whose supply chain turns out to be opaque — has become intense.

The novel food regime — what it actually requires

A novel food is defined under UK retained law as any food that was not consumed to a significant degree by humans in the UK or EU prior to 15 May 1997. The threshold for "significant degree" is assessed on a case-by-case basis — there is no simple list that covers every ingredient, and borderline cases require legal and scientific analysis, not a Google search.

Novel foods require pre-market authorisation from the Food Standards Agency (FSA) in Great Britain before they can legally be placed on the market. The authorisation process requires submission of a comprehensive safety dossier — demonstrating safety at the proposed conditions of use, absence of nutritional disadvantage, and absence of misleading claims. The process takes a minimum of 18 months from submission. Most take longer.

Placing an unauthorised novel food on the UK market is a criminal offence. Enforcement is handled by local authority Trading Standards officers. Penalties include product seizure, forced recall, prosecution of directors, and — for brands with retail listings — the commercial devastation of a public delisting.

CBD — the market that illustrates every problem

CBD (cannabidiol) and the broader cannabinoid category has become the most prominent example of a novel ingredient market where commercial momentum has consistently outpaced regulatory compliance. Thousands of CBD food products were sold in the UK for years before the FSA formally confirmed their novel food status in 2019. Many continue to be sold in a state of regulatory ambiguity — with validated applications pending but no authorisation granted, and a tolerance framework that has been progressively tightened.

As of 2026, no CBD food product has received full novel food authorisation in Great Britain. Every CBD food product sold in the UK market exists in a state of regulatory contingency — dependent on the outcome of ongoing FSA review processes. The commercial risk this creates for brands is real and underappreciated. A brand that has built its entire product range around a CBD ingredient that the FSA refuses to authorise does not have a product range.

The CBD ingredient supply chain carries specific and serious provenance risks that are not present in more mature ingredient categories. The industrial hemp cultivation and extraction industry is young, globally fragmented, and inconsistently regulated across source countries. The result is a market where quality, purity, and compliance vary enormously — and where the difference between a legitimate, clean extract and a non-compliant one is not visible to the eye or detectable without laboratory analysis.

Key provenance risks in cannabinoid ingredients include: THC content above legal thresholds in the raw material or finished extract; pesticide and heavy metal contamination from agricultural practices in source countries; adulteration with synthetic cannabinoids; mislabelled CBD concentration; and — for products making regulatory claims about the source variety — inability to verify the declared hemp cultivar.

A certificate of analysis from a supplier is not sufficient verification of any of these parameters. COAs are only as reliable as the testing laboratory that produced them and the chain of custody that connects the tested sample to the material actually supplied. Independent third-party testing of every batch, by an accredited laboratory with no commercial relationship to the supplier, is the minimum standard for responsible CBD ingredient sourcing.

Provenance and supply chain controls — the non-negotiable foundation

The provenance challenge is not unique to CBD. It applies across the functional and novel ingredient category, and it has three dimensions that brands must address explicitly — not just assume their supplier has covered.

Is the ingredient what it says it is, at the concentration stated, free from the contaminants specified? This sounds basic. It is not reliably delivered without systematic controls. The global botanical ingredient market — which supplies the raw materials for most functional food and supplement products — has documented adulteration problems in multiple categories. Studies of commercially available herbal products have identified species substitution, dilution with lower-cost materials, and contamination with undeclared pharmacologically active compounds. Without independent analytical verification, a brand cannot make product claims with integrity.

For regulatory compliance, retailer requirements, and consumer trust, the ability to trace an ingredient from the finished product back to its origin is essential. For novel foods, this traceability is a requirement of the authorisation documentation. For products making sustainability, ethical, or geographic origin claims, it is a trading standards obligation. For products sold through major retailers, it will be audited.

Traceability means more than a supplier being able to name the country of origin. It means documented, verifiable records of the farm, cooperative, or supplier from which raw materials were sourced; the processing steps and facilities through which those materials passed; and the batch-level linkage between finished product and raw material. This infrastructure does not exist automatically — it must be specified, contracted for, and verified.

The sourcing of botanical ingredients — including many of the most commercially popular functional ingredients — often involves supply chains in lower-income countries where labour standards, environmental practices, and land rights may be inadequate. Brands making sustainability or ethical claims, or supplying to major retailers with responsible sourcing requirements, need to verify their ingredient supply chain against these standards — not rely on their supplier's assurance that everything is fine.

Health claims: the layer that compounds the risk

Even if an ingredient is approved as a novel food, you may not be able to make the health claims your brand positioning depends on. The UK and EU health claim frameworks restrict permitted claims to those that appear on an authorised register — and for novel ingredients, claim authorisation typically cannot proceed until novel food authorisation is complete.

The practical consequence is that brands in the functional food and supplement space frequently use implied health positioning — language that suggests a benefit without explicitly stating an authorised claim. "Supports your wellbeing." "Helps you feel your best." "Formulated for focus." This implied positioning creates its own legal risk under the Food Information to Consumers Regulation and the Consumer Protection from Unfair Trading Regulations. Regulators are increasingly sophisticated about the difference between technically compliant label copy and misleading consumer communication.

Getting health claims right requires a qualified food regulatory professional — not marketing copywriting instinct — reviewing every piece of consumer-facing communication before it is published.

Who you actually need — and who you do not

This is the section most often skipped and most often regretted. Navigating novel foods, ingredient regulatory status, health claims, and supply chain compliance is not a job for generalists. It requires a specific combination of qualified professionals — and the discipline to engage them before, not after, problems emerge.

A reference table of novel food ingredients — regulatory snapshot

The quality control framework that actually protects you

Across every novel and functional ingredient category, the brands that operate safely and sustainably are those that have built formal quality controls into their ingredient procurement — not those that rely on supplier assurance. The minimum framework should include:

1. Qualified supplier approval process. Every ingredient supplier must be formally approved against defined criteria before use — including regulatory status confirmation, certification verification, audit history review, and financial health assessment. This should be documented and maintained by a qualified person, not completed informally.
2. Written specifications for every ingredient. A specification document for each ingredient that sets out: identity parameters, purity standards, permitted contaminants and their limits, country of origin requirements, certification requirements, and packaging and labelling requirements. Signed by both the brand and the supplier. Reviewed annually.
3. Independent batch testing protocol. A defined testing programme for each ingredient — specifying which parameters are tested, by which accredited laboratory, at what frequency, and what the out-of-specification response procedure is. The testing laboratory must be independent of the supplier and the manufacturer. Results must be reviewed by a qualified food scientist before the batch is approved for use.
4. Regulatory status monitoring. Novel food and health claim regulatory positions change. A brand whose compliance position depends on the current status of an ingredient must monitor regulatory developments and update their position accordingly. This requires a retained regulatory consultant who flags relevant changes — not a Google Alert.
5. Document control and traceability. Batch records, COAs, testing results, and supplier documentation must be retained and retrievable for the shelf life of the product plus a defined period (typically 3–5 years minimum). In the event of a recall, an enforcement investigation, or a retailer audit, this documentation is your defence. If it does not exist, you have no defence.